Lilly discusses R&D pipeline with investors
NEW YORK — Innovation took center stage Thursday as Eli Lilly laid out its future growth strategies at a meeting with investors.
At its “Bridging to the Future” meeting, Lilly said it had 70 drugs in its research and development pipeline, including 33 in phases 2 and 3. The company said it expects at least 10 new drugs to enter phase 3 this year, including drugs in such areas as cancer, diabetes and neuroscience, as well as new therapeutic areas, such as autoimmune disorders.
“At Lilly, our future relies upon our ability to successfully discover and develop innovative medicines that address unmet patient needs,” Lilly president, chairman and CEO John Lechleiter said. “We’re pursuing an R&D-based strategy in full knowledge that the bar for innovative medicines has never been higher and that our industry faces many challenges.”
Physicians urge FDA not to approve Truvada
LOS ANGELES — A group of physicians is urging the Food and Drug Administration not to approve a drug made by Gilead Sciences for the prevention of HIV infection.
Fifty-five physicians signed a letter spearheaded by the AIDS Healthcare Foundation citing concerns about the use of Gilead’s Truvada (tenofovir disoproxil fumarate and emtricitabine) for “pre-exposure prophylaxis,” or PrEP. Concerns included the risk of a decrease in condom use and a lack of information showing proper use in “real world” situations.
“As medical care providers, we strongly support continued research on the prevention of HIV, but oppose approval of a pre-exposure prophylaxis that runs the risk of contributing to the spread of HIV and drug-resistant viruses,” the physicians wrote. “Our first obligation is to do no harm to individuals and to the public health.”
NACDS conference exhibitors donate 6.5 tons of consumer goods through Conventions C.A.R.E.
ALEXANDRIA, Va. — As part of this year’s National Association of Chain Drug Stores Marketplace Conference in Boston, which came to a close Tuesday, NACDS conference exhibitors and Conventions C.A.R.E. dispersed 6.5 tons of consumer goods to various charitable organizations throughout the Greater Boston community.
NACDS worked with the Massachusetts Convention Center Authority’s Conventions C.A.R.E. program, which was established by the MCCA to benefit convention and trade show exhibitors, the convention centers and local nonprofits. Exhibitors are saved the time and expense of shipping unneeded goods after a show ends, while local nonprofits benefit from useful donations, such as boxes of toiletries or office supplies. The MCCA and its partners in turn help divert these items from local landfills. Marketplace exhibitors donated such products as cosmetics, health and hygiene products, food and beverages, household supplies and other consumer products available in chain pharmacies.
"During these challenging economic times, we are deeply grateful to NACDS’ associate member companies for their product contributions to help those in need in the Boston community," NACDS president and CEO Steve Anderson said. "NACDS is grateful to have a partner in the Conventions C.A.R.E. program to distribute these goods to local nonprofit groups."